In this target trial emulation, glucagon-like peptide-1 receptor agonists (GLP-1RAs) were associated with a lower risk of ...

Glucagon-like peptite-1 (GLP-1) receptor agonists, such as Wegovy and Ozempic, have taken the food industry by storm. With ...

For older adults with type 2 diabetes (T2D), use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class ...

In response to the growing interest in glucagon-like peptide-1 (GLP-1) weight-loss medications and the cost challenges employers face to offer coverage, Liviniti, a national leader in PBM innovation, ...

Diabetes and obesity have become pressing health issues worldwide. Glucagon-like peptide-1 (GLP-1) receptor agonists, a class of medications widely used in the treatment of type 2 diabetes (T2D), have ...

The use of glucagon-like peptide-1 receptor agonists , such as semaglutide—marketed under brand names like Wegovy and Ozempic—has surged among adolescents and young adults. Between 2020 and 2023, the ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

Evidence suggests no increased risk The use of glucagon-like peptide-1 (GLP-1) receptor agonists has surged in recent years, driven by their benefits in glucose control in type 2 diabetes, weight ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarteritic ...

Compared to other diabetes medications, GLP-1 drugs like Ozempic were associated with a lower risk for depression in a recent ...

Some studies link GLP-1 drugs for diabetes with neuroprotective benefits but others say that some of these drugs may increase ...